Major depressive disorder is one of the most common mental health conditions in the world. Millions of people live with it every day, and for many, the illness can completely change their lives.
Depression is much more than simply feeling sad for a short time.
It can cause deep emotional pain, exhaustion, hopelessness, loss of interest in life, trouble sleeping, changes in appetite, difficulty concentrating, and even suicidal thoughts.
For some people, depression becomes so severe that getting through daily activities feels almost impossible. Relationships, work, physical health, and quality of life can all suffer.
Although many antidepressant medications are available, doctors have known for years that these treatments do not work for everyone.
In fact, researchers estimate that at least one-third of people with major depression do not improve even after trying two or more standard antidepressant treatments. Doctors call this condition treatment-resistant depression.
For these patients, finding an effective treatment can become a long and painful process filled with disappointment and frustration.
Now, researchers from UConn School of Medicine, Harvard, Yale, the University of Toronto, and several other institutions have reported promising findings that may offer new hope for people struggling with difficult-to-treat depression.
The studies were published in the medical journal JAMA Psychiatry. Instead of creating completely new drugs, the researchers examined whether existing medications could be used in new ways to help patients who did not respond to traditional antidepressants.
One of the studies focused on ketamine, a drug first developed many years ago as a fast-acting anesthetic used during surgery. In recent years, scientists discovered that ketamine may also have powerful effects on depression, especially for people with severe symptoms or suicidal thoughts.
Unlike traditional antidepressants, which often take weeks to start working, ketamine can sometimes improve mood within hours or days. This rapid effect has attracted enormous interest from doctors and researchers.
The US Food and Drug Administration has already approved a nasal spray form of ketamine called esketamine for certain patients with depression. However, intravenous ketamine, which is given directly into the bloodstream through a drip, is still being studied carefully.
In the new research, scientists analyzed 26 randomized controlled trials that compared intravenous ketamine with placebo treatments or other controls.
Randomized controlled trials are considered one of the strongest forms of medical evidence because they help reduce bias and allow researchers to compare treatments fairly.
The results showed that intravenous ketamine was clearly more effective than placebo treatments over the short term.
Many patients experienced rapid improvements in depressive symptoms within just a few days. The treatment also appeared to reduce suicidal thoughts very quickly in people at immediate risk of harming themselves.
This finding is especially important because suicidal crises often require urgent treatment. Traditional antidepressants usually work too slowly during emergencies, but ketamine may provide faster relief during critical situations.
However, the researchers also found that the benefits of ketamine became less strong after several weeks. This suggests that while ketamine may provide rapid short-term relief, scientists still need to study how to maintain long-term improvements safely.
The researchers also found that intravenous ketamine worked about as well as esketamine nasal spray. This may help doctors better understand which form of treatment may be most suitable for different patients.
The second study looked at another possible treatment strategy. Researchers studied combinations of antidepressants and antipsychotic medications for people with treatment-resistant depression.
Antipsychotic drugs were originally designed to treat conditions such as schizophrenia and bipolar disorder. However, doctors sometimes use certain antipsychotic medications together with antidepressants to strengthen the effects of depression treatment.
The researchers examined data from 22 previous studies to compare how well these medication combinations worked and how likely patients were to stop taking them because of side effects.
Some antipsychotic medications appeared to significantly reduce depressive symptoms when combined with antidepressants. However, one medication called lumateperone showed a complicated result. It appeared to be among the most effective drugs for reducing depression symptoms, but it was also the medication most likely to be discontinued because patients experienced side effects.
This highlights one of the biggest challenges in mental health treatment. A medication may work well for symptoms but still be difficult for some patients to tolerate. Doctors must often carefully balance benefits and side effects when choosing treatment plans.
The researchers say these findings may help psychiatrists and other healthcare providers make better decisions for patients with moderate to severe depression who have not improved with standard treatments.
Dr. T. Greg Rhee, a psychiatric epidemiologist at UConn School of Medicine, explained that these newer treatment approaches may provide important alternatives for patients who previously had very limited options.
The researchers also said they plan to continue studying the long-term safety and effectiveness of these treatments using large population-level studies.
The findings are important because they reflect a growing shift in depression research. Scientists are beginning to recognize that depression is not the same for every person.
Different biological systems in the brain may contribute to the illness in different ways, which means some people may need very different types of treatment.
The research also shows how urgently better depression treatments are needed. Depression remains one of the leading causes of disability worldwide, and many patients continue suffering even after trying multiple medications.
At the same time, experts caution that ketamine and antipsychotic medications are not simple cures. Both treatments can carry risks and side effects, and they should only be used under medical supervision.
More research is still needed to fully understand which patients benefit most and how these treatments can be used safely over time.
Still, the new studies offer real hope for people living with severe depression. For patients who have spent years searching for relief, these findings suggest that newer treatment strategies may eventually open the door to better care and improved quality of life.
The research was published in JAMA Psychiatry.
In reviewing these findings, the studies appear strong because they combined evidence from many earlier clinical trials rather than relying on only one small experiment. This increases confidence in the results.
The ketamine findings are especially important because they show rapid reductions in suicidal thoughts, which could potentially save lives during mental health emergencies. However, the weakening effect after several weeks also shows that ketamine may not yet be a complete long-term solution.
The second study highlights both the promise and difficulty of combining medications. Some antipsychotic drugs may help patients with treatment-resistant depression, but side effects remain a major challenge.
Overall, the studies suggest that future depression treatment may become more personalized, with doctors choosing different therapies based on each patient’s symptoms, risks, and response to treatment.
If you care about depression, please read studies that vegetarian diet may increase your depression risk, and Vitamin D could help reduce depression symptoms.
For more information about health, please see recent studies that ultra-processed foods may make you feel depressed, and these antioxidants could help reduce the risk of dementia.
